# SenzaGen

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/senzagen).

## Overview

SenzaGen is a Swedish life science company focused on nonanimal testing for chemical safety and product efficacy. Its core offering combines proprietary GARD® testing methods, consulting services, and laboratory work delivered through its own facilities in Sweden and Italy, supported by a network of partners.

## Products & services

• GARD® skin sensitization testing
• Nonanimal toxicology testing services
• Regulatory safety assessment consulting
• VitroScreen efficacy testing
• GARD®air respiratory sensitization testing
• Customized organoid-based testing

- **Regulatory toxicology testing** (60%) — Nonanimal tests used to assess skin and respiratory sensitization and chemical safety.
- **Efficacy testing** (20%) — Human-relevant preclinical testing using tissue models and organoids for product performance.
- **Consulting and regulatory support** (10%) — Scientific and regulatory guidance that helps customers select and interpret tests.
- **Partner and license-based testing** (10%) — Testing capacity and market access delivered through distributors and license partners.

- GARD® skin sensitization testing
- Nonanimal toxicology testing services
- Regulatory safety assessment consulting
- VitroScreen efficacy testing
- GARD®air respiratory sensitization testing
- Customized organoid-based testing

## Customers

SenzaGen sells primarily to large multinational companies that need testing during product development, reformulation, and regulatory submission. Its customer base spans cosmetics, chemicals, medical devices, pharmaceuticals, and nutrition/food additives, where buyers need evidence that products meet safety requirements without animal testing.

- **Large multinational direct-sales customers** (primary) — Buy GARD® and related lab services directly for recurring regulatory and development testing.
- **Cosmetics and personal care companies** (primary) — Use skin sensitization and efficacy testing when launching or reformulating products.
- **Chemical and industrial companies** (primary) — Buy toxicology testing to support product safety and regulatory compliance.
- **Medical device customers** (secondary) — Use sensitization testing to support ISO and regulatory requirements.
- **Distributor and license partner channel** (secondary) — Partners extend market reach and provide flexible testing capacity.

- Large multinational corporations with recurring testing needs
- Cosmetics companies evaluating skin sensitization and product safety
- Chemical manufacturers needing regulatory toxicology evidence
- Medical device firms seeking ISO-aligned sensitization testing
- Pharmaceutical and nutrition customers with preclinical testing needs

## Geography

SenzaGen is headquartered in Lund, Sweden and operates GLP-approved laboratories in Sweden and Italy. The company’s commercial focus is Europe, with selective targeting of large multinational customers in North America, especially the United States, and it also uses international distributors and license partners to broaden reach.

- Headquartered in Lund, Sweden
- GLP-approved laboratories in Sweden and Italy
- Primary commercial focus on Europe
- Selective sales targeting in the United States
- Partner network supports expansion into new countries

## Strategy

SenzaGen’s strategy is built around expanding adoption of GARD® through regulatory approvals, technology upgrades, and broader market acceptance. It combines direct sales to large recurring customers with partner channels to scale internationally while building a larger portfolio of nonanimal test methods.

- **Broaden regulatory acceptance of GARD®** (medium-term) — Regulatory approvals increase customer adoption and support repeat testing demand.
- **Scale direct sales to multinational customers** (short-term) — Large recurring customers fit the lab-based model and improve repeat order visibility.
- **Expand through partners and new markets** (medium-term) — Distributors and licensees extend reach without requiring full local infrastructure.
- **Launch new nonanimal test methods** (long-term) — A broader portfolio increases addressable markets and reduces reliance on one assay family.

- Expand GARD® through regulatory approvals and standards inclusion
- Grow direct sales to multinational customers with recurring needs
- Use distributors and license partners to scale geographic reach
- Develop new test methods and complementary applications
- Strengthen the commercial model around own labs and partner capacity

## Risks

SenzaGen faces execution risk in market expansion, product development, and reliance on partners that help scale sales and capacity. As a testing company with proprietary methods, it also depends on regulatory acceptance, patent protection, customer adoption, and access to capital to fund growth initiatives.

- **Market growth and expansion execution** [high] — Entering new countries and regions can create delays, organizational strain, and lost revenue.
- **Distributor and license partner dependence** [high] — A small but important share of revenue and capacity depends on third-party partners fulfilling obligations.
- **Financing needs** [medium] — Growth initiatives may require additional funding if market penetration is slower than planned.
- **Patent and IP protection** [medium] — Commercial value depends on patents and proprietary methods remaining defensible.
- **Product development and regulatory adoption** [high] — New tests need validation and acceptance before they can generate meaningful revenue.

- Market expansion may be delayed or harder than expected
- Partner sales depend on distributors and licensees performing well
- Product development may not deliver timely commercial adoption
- Regulatory approvals can take time and may not translate into demand
- Patent protection may not fully prevent imitation
- Additional capital may be needed if growth investments outpace cash generation

## Accounting

SenzaGen’s reporting is shaped by IFRS 16 lease capitalization, which moves operating lease costs into depreciation and interest and changes EBITDA-style comparability. The company also relies on judgment in areas such as revenue recognition for testing services, estimates around goodwill and intangible assets from acquisitions, and first-time IFRS adoption adjustments that affect comparatives.

- **IFRS 16 leases** — Right-of-use assets, lease liabilities, depreciation, and interest expense
- **Revenue recognition for testing services** — Quarterly revenue volatility and contract asset/liability balances
- **Goodwill and intangible assets** — Potential non-cash impairment charges
- **IFRS first-time adoption** — Comparability between 2024 K3 and IFRS figures

- IFRS 16 lease accounting affects EBITDA, assets, and liabilities
- Testing service revenue may depend on contract timing and delivery
- Goodwill and acquired intangibles require impairment testing
- First-time IFRS adoption affects comparability with prior periods
- Foreign currency translation can affect reported operating results

---

*Last updated: 2026-08-11T04:04:55.739042+00:00*